Browse articles from EyeWorld.org related to Fuchs. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
Corneal edema after cataract surgery is expected to an extent, but as postop recovery stretches to 1 month or beyond, surgeons begin to treat the situation differently. Three surgeons discussed preop contributors, prevention, diagnosis, and treatment of prolonged corneal edema.
➤ Research: quest for cataract reversal continues ➤ First allogenic cell therapy for treating corneal endothelial disease ➤ Enrollment complete in Phase 2b geographic atrophy treatment study ➤ European agency maintains negative opinion for intravitreal pegcetacoplan for geographic atrophy ➤ Companies partner to further development of new glaucoma drug ➤ ASCRS news and events
When planning cataract surgery, it’s important to pay particular attention to patients who may have a compromised cornea or endothelial damage. Two cornea specialists spoke with EyeWorld about considerations for cataract surgery in these eyes.
➤ Orphan drug designation granted for retinitis pigmentosa treatment ➤ Licensing agreement for progressive myopia treatment ➤ Study: Gene editing prevents Fuchs in mice ➤ Enrollment complete for Phase 3 program evaluating anti-inflammatory, immunomodulation drug for DED ➤ ASCRS news and events
➤ FDA approves new presbyopia-correcting IOL ➤ New way to evaluate sickle cell retinopathy ➤ Positive Phase 2a data on novel, topical dry eye disease drug candidate ➤ Second Phase 3 trial initiated for Demodex blepharitis treatment ➤ Large-scale, randomized controlled trial replicated with real-world data set ➤ ASCRS events
➤ Investigating adjuvant therapy to DSO for Fuchs ➤ FDA approves loteprednol etabonate ophthalmic gel ➤ Pilot study: Photobiomodulation improves BCVA in patients with dry AMD ➤ Positive interim data in trial for gene therapy for GA ➤ Four Phase 3 studies of faricimab show up to 4-month treatment intervals for DME and wet AMD